Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin to Prevent Liver Complications in Chronic Hepatitis B and Diabetes Mellitus
NCT06364930Phase 4Recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Mar 2024
- Primary completion
- Oct 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in Chronic Hepatitis B (CHB), sponsored by The Chinese University of Hong Kong. Started Mar 2024; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06364930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06364930.